Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-18T22:11:06.452Z Has data issue: false hasContentIssue false
  • English
  • Français

¿Merece la pena cambiar de antipsicóticos convencionales a atípicos a pacientes ambulatorios esquizofrénicos clínicamente estables con síntomas residuales, efectos secundarios, o ambas cosas, de leves a moderados? Un estudio prospectivo distribuido al azar con olanzapina

Published online by Cambridge University Press:  12 May 2020

Björn Appelberg ,
Katinka Tuiskua  and
Grigori Joffe
Björn Appelberg
Affiliation:
Departamento de Psiquiatría, Hospital Central de la Universidad de Helsinki, POB 590, 00029 Hus, Finlandia.
Grigori Joffe
Affiliation:
Hospital Psiquiátrico de Kellokoski, Finlandia.
Get access

Resumen

Se distribuyó al azar a cincuenta pacientes ambulatorios esquizofrénicos clínicamente estables que sufrían de síntomas esquizofrénicos residuales, efectos secundarios neurológicos o ambas cosas para que continuaran su(s) neuroléptico(s) convencional(es) o lo(s) cambiaran por olanzapina. Después de doce semanas, los pacientes con olanzapina mostraban mejoría significativa en los efectos secundarios neurológicos y los síntomas psicóticos, comparado con los pacientes con antipsicóticos convencionales.

Keywords

EsquizofreniaPacientes ambulatoriosEnsayo distribuido al azarAntipsicóticos atípicosOlanzapina
Type
Comunicación breve
Information
European Psychiatry (Ed. Española) , Volume 12 , Issue 4 , May 2005 , pp. 247 - 249
Copyright
Copyright © European Psychiatric Association 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Appelberg B., Tuisku K, Joffe G. Is it worth while changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics? A prospective, randomised study with olanzapine. Eur Psychiatry 2004;19:516- 518.

References

Bibliografía

[1] American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM IV. Washington DC: APA; 1995.Google Scholar
[2]Barnes, TR. A rating scale for drug-induce akathisia. Br J Psychiatry 1989; 154: 672-66.CrossRefGoogle Scholar
[3]Geddes, JFreemantle, NHarrison, P, Bebbington R Atypical antipsychotics in the treatment of schizophrenia: systematic OverView and meta-regression analysis. BMJ 2000; 321 (7273): 1371-6.Google Scholar
[4]Kay, SRFiszbein, SOpler, LA. The positive and negative syndrome scale for schizophrenia. Schizophr Bull 1987; 13: 261-76.CrossRefGoogle Scholar
[5]Leucht, SBarnes, TKissling, WEngel, RCorrell, CKanc, J. Relapse prevention for schizophrenia with new generation antipsychotics: a systematic review and explorative meta-analysis of randomised controlled triais. Am J Psychiatry 2003; 160(7): 1209-22.CrossRefGoogle Scholar
[6]Leucht, SWahlbeck, KHermann, JKissling, W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581-9.CrossRefGoogle ScholarPubMed
[7]Rummel, CHamann, JKissling, WLeucht, S. New generation antipsychotics for first episode schizophrenia. Cochrane Database Syst Rev 2003;(4) CD004410.Google Scholar
[8]Simpson, GMAngus, JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;(Suppl. 212): 11–29.Google ScholarPubMed